

1 **Supplementary Materials**

2

3 **Materials and Methods**

4 **Cell culture and transfection.** The human hepatoma cell line HepG2.2.15 cells  
5 harboring integrated dimers of the HBV genome and Huh7 cells without an integrated  
6 HBV genome were used as described previously (Ni et al., 2010). Primary human  
7 hepatocytes were kindly provided by Dr. Ruth Broering (University Hospital Essen,  
8 Germany).

9 **Plasmids and reagents.** The plasmids pSM2 and GFP-LC3 have been described  
10 previously (Lin et al., 2016). The plasmids HA-HBs and mCherry-HBs are kept and  
11 stored in our lab. The plasmids GFP-Rab7 WT (12605), GFP-Rab7 DN (12660), and  
12 DsRed-PLEKHM1 (73592), were purchased from Addgene (Cambridge, MA, USA).  
13 The siRNA sequences used are shown in Table S1. Chemical inhibitors CID1067700  
14 (SML0545), rapamycin (R8781), 3-MA (M928), and CQ (C6628) were purchased from  
15 Sigma-Aldrich (St. Louis, MO, USA).

16 **Construction of the mCherry-HBs plasmid.** The mCherry-HBs plasmid was  
17 constructed by inserting the HBsAg WT (nt160-841, GenBank accession number,  
18 AF282918), tissue plasminogen activator (tPA-SP), and mCherry tag sequences into a  
19 pcDNA3.1(+) backbone vector (Fan et al., 2008; Wu et al., 2012). A 69-bp signal  
20 sequence for tPA-SP has been used as a heterologous leader sequence (Jalah et al., 2007)  
21 to drive HBsAg into the cellular secretion pathway. The primers used for the  
22 construction of mCherry-HBs are listed in Table S2.

23 **Analysis of HBV replication and gene expression.** HBV RIs from intracellular core

24 particles were extracted from hepatoma cell lines and detected by Southern blot  
25 according to published protocols (Ni et al., 2010). HBV progeny DNA was extracted  
26 from culture supernatants using the DNA Blood Mini Kit (Qiagen, 51106) and  
27 quantified using quantitative real-time PCR (Invitrogen, 11733-046). HBV RNA in  
28 cells was measured using real-time RT-PCR assays (Qiagen, 204154) (the sequences  
29 of primers are shown in Table S2). The levels of intracellular HBsAg and secreted  
30 HBsAg and HBeAg in culture supernatants were determined using the Architect  
31 System and HBsAg and HBeAg CMIA kits (Abbott Laboratories, Chicago, IL, USA)  
32 according to the manufacturer's instructions. HBV nucleocapsids in the cell lysates  
33 were analyzed by native agarose gel electrophoresis and then detected by western blot.  
34 The encapsidated HBV DNA in nucleocapsids was detected by Southern blot.

35 **Western blot analysis.** Western blot analysis was performed as described previously  
36 (Lin et al., 2016). Briefly, prepared cells were washed with phosphate buffered saline  
37 and lysed with 1× lysis buffer (Cell Signaling, 7723). Protein samples were resolved by  
38 sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then electro-transferred  
39 to nitrocellulose membranes. The membranes were incubated with the indicated  
40 primary antibodies overnight at 4 °C after being blocked with 5% milk in 1× TBST.  
41 Antibodies against the following proteins were used: anti-Rab7 (Cell Signaling, 9367),  
42 anti-PLEKHM1 (Cell Signaling, 66012), anti-Flag (Cell Signaling, 2368), anti-LAMP1  
43 (Sigma, 9091), anti-HBcAg (Abcam, ab8637), anti-p62 (Abcam, ab91526), anti-LC3  
44 (MBL, PM036), and beta-actin (Sigma, A5441). The membranes were washed with 1×  
45 TBST and incubated (as appropriate) with a secondary peroxidase-affiniPure Rabbit

46 anti-mouse IgG antibody (Jackson ImmunoResearch, 315-035-048) or a peroxidase-  
47 affiniPure goat anti-rabbit IgG antibody (Jackson ImmunoResearch, 111-035-045).  
48 Immunoreactive bands were visualized using an enhanced chemiluminescence system  
49 (GE Healthcare, RPN2106).

50 **Real-time RT-PCR assay.** Total RNA was extracted with TRIzol (Invitrogen, 15596-  
51 018), followed by digestion with the DNase Set (Roche, 10104159001). QuantiTect  
52 primer assays of human beta-actin (QT01680476) and Rab7 (QT00004949) were  
53 purchased from Qiagen Company. All the other sequences of primers used in the  
54 present study are shown in Table S2. For each sample, RT-PCR was performed in  
55 duplicate by using real-time RT-PCR assays (Qiagen, 204154). The expression levels  
56 of each gene are presented as values normalized against  $10^6$  copies of beta-actin  
57 transcripts.


58 **Confocal microscopy.** For immunofluorescence staining, Huh7 cells were grown on  
59 cover slips and co-transfected with the GFP-LC3 plasmid and siRNAs or other plasmids  
60 as indicated in each experiment. After 48 h, cells were washed with phosphate buffer  
61 solution, fixed in 4% paraformaldehyde, and permeabilized with 0.1% Triton X-100.  
62 The cells were incubated with primary antibodies and then stained with Alexa Fluor  
63 488- (Jackson ImmunoResearch, 111-545-003), Alexa Fluor 594- (Jackson  
64 ImmunoResearch, 111-605-003), or Alexa Fluor 647- (Jackson ImmunoResearch, 111-  
65 605-003) conjugated Goat anti-Rabbit IgG (H+L). The nuclei were stained with 6-  
66 diamidino-2-phenylindole (DAPI), and the distribution of GFP-tagged LC3 protein was  
67 visualized with an LSM 710 confocal microscope (Zeiss, Jena, Germany) with a Plan-  
68 Apochromat 63×/1.40 oil Iris M27 objective. The number of LC3 puncta in cells was  
69 quantified as described previously (Lin et al., 2016). The co-localization of HBsAg and

70 relative organelle marker proteins was analyzed using ImageJ software.

71 **Statistical analyses.** Statistical analyses were performed using Graph Pad Prism  
72 software version 5.1 (La Jolla, CA, USA). Analysis of variance with two-tailed  
73 Student's *t* test or by one-way ANOVA with a Tukey posttest was used to determine  
74 significant differences. Differences were considered statistically significant when  $P <$   
75 0.05. All experiments were repeated independently at least three times.

76

**Fig. S1**




78

79 **Figure S1. Inhibition of different autophagic phases inversely affects HBV**  
 80 **replication.** (A) HepG2.2.15 cells were treated with autophagy inhibitors 10 mM 3-  
 81 methyladenine (3-MA), 5  $\mu$ M CID1067700 (CID), and 10  $\mu$ M chloroquine (CQ) for 48  
 82 h. LC3 puncta in the cells were analyzed by confocal microscopy. Bars, 5  $\mu$ m.  
 83 HepG2.2.15 cells (B and C) or primary hepatocytes with HBV virion infection at an  
 84 MOI of 30 (D and E) were treated with autophagy inhibitors as in (A). LC3, p62, and  
 85 HBcAg expression was analyzed by western blot with beta-actin as a loading control.  
 86 Analysis of secreted HBsAg and HBeAg from culture supernatants and intracellular  
 87 HBsAg from cell lysates was performed using a chemiluminescent microparticle

88 immunoassay (CMIA). The levels of HBV genomes in culture supernatants were  
89 determined by quantitative real-time PCR. HBV replicative intermediates in cells were  
90 detected by Southern blot. S/CO = signal to cutoff ratio; RC: relaxed circular DNA; SS  
91 = single-stranded DNA. The data are shown as mean  $\pm$  SEM. \*,#  $P < 0.05$ ; \*\*,##  $P <$   
92 0.01; ns, not significant.

93

**Fig. S2**



94

95 **Figure S2. Rab7 silencing induces incomplete autophagy.** (A) Huh7 cells were

96 cotransfected with GFP-LC3 plasmids and 20 nM siRab7 or control siRNA (siR-C).

97 After 48 h, the transfected cells were imaged by confocal microscopy. (B) HepG2.2.15

98 cells were transfected with 20 nM siRab7 or siR-C and harvested after 96 h. Analysis

99 of secreted HBsAg and HBeAg in culture supernatants and intracellular HBsAg from

100 cell lysates was performed by CMIA. Analyses of HBV genomes in culture


101 supernatants and HBV replicative intermediates inside the cells were separately

102 performed as described above. S/CO = signal to cutoff ratio; RC: relaxed circular DNA;

103 SS = single-stranded DNA. The data are shown as mean  $\pm$  SEM. \*  $P < 0.05$ ; \*\*  $P <$

104 0.01.

**Fig. S3**



105

106 **Figure S3. Silencing of Rab7 effector PLEKHM1 increases HBV replication and**

107 **HBsAg production.** (A) Huh7 cells were cotransfected with GFP-LC3 plasmids and

108 20 nM siRNAs against PLEKHM1 (siPLEKHM1) or control siRNA (siR-C). After 48

109 h, the transfected cells were imaged by confocal microscopy. The cells were treated

110 with 10  $\mu$ M CQ for 24 h as a positive control. (B) HepG2.2.15 cells were transfected

111 with 20 nM siPLEKHM1 or siR-C and harvested after 96 h. Analysis of secreted

112 HBsAg and HBeAg in culture supernatants and intracellular HBsAg from cell lysates

113 was performed by CMIA. Analyses of HBV genomes in culture supernatants and HBV


114 replicative intermediates inside the cells were separately performed as described above.

115 S/CO = signal to cutoff ratio; RC: relaxed circular DNA; SS = single-stranded DNA.

116 The data are shown as mean  $\pm$  SEM. \*  $P < 0.05$ ; \*\*  $P < 0.01$ .

117

**Fig. S4**



118

119 **Figure S4. Rab7 silencing does not increase HBV transcription and promoter**

120 **activity.** (A) HepG2.2.15 cells were transfected with 20 nM siRab7 or control siRNA

121 (siR-C) and harvested after 72 h. HBV RNA levels were analyzed by real-time RT-PCR

122 assay. (B) Luciferase reporters containing the HBV promoter regions pSP1, pSP2, pCP,

123 and pXP were co-transfected with siRab7 or siR-C at 20 nM into Huh7 cells,

124 respectively. At 48 h, firefly and Renilla luciferase activities were analyzed using a

125 Dual-Glo luciferase reporter assay. The relative luciferase expression was calculated by

126 fold-change and normalized to siR-C. The data are shown as mean  $\pm$  SEM. \*  $P < 0.05$ ;

127 \*\*  $P < 0.01$ ; ns, not significant.

128

129 **Supplementary Tables**

130 **Table S1. List of siRNAs used in this study**

Name	Product Name	Company	Target sequence
siR-C	Allstars Negative Control siRNA	Qiagen	Proprietary
siRab7	Hs_RAB7_5 FlexiTube siRNA	Qiagen	CACGTAGGCCTTCAACACAAT
siPLEKHM1	Hs_PLEKHM1_3 FlexiTube siRNA	Qiagen	CACCGCCATGGCCCACATTAA

131

132 **Table S2 Primers used for Real-time PCR and cloning**

Gene name	Application	Type	Sequence 5'-3'	Position of 5'-base
HBV DNA	real time PCR	Forward	GTTGCCCGTTTGCCTCTAATTC	465
HBV DNA	real time PCR	Reverse	GGAGGGATACATAGAGGTTTCCTT	563
HBV RNA	real time RT-PCR	Forward	CCGTCTGTGCCTTCTCATCT	1551
HBV RNA	real time RT-PCR	Reverse	TAATCTCCTCCCCAACTCC	1756
F-tPA-SP	Cloning	Forward	GACAAGCTTATGGATGCAATGAAG AGAGGGCTCTGCTGTGTGCTGCTG CTGTGTG	Ref.(Fan et al., 2008; Wu et al., 2012)
R-tPA-SP	Cloning	Reverse	CCAGAATTCGCTGGGCGAAACGAA GACTGCTCCACACAGCAGCAGCAC ACAGCAGAG	Ref. (Fan et al., 2008; Wu et al., 2012)
F-mCherry	Cloning	Forward	CAGGAATTCATGGTGAGCAAGGGC	Ref. (Fan et al., 2008; Wu et al., 2012)
R-mCherry	Cloning	Reverse	GTGGGATCCTCCTGAACCCTTGAC AGCTCGTCCAT	Ref. (Fan et al., 2008; Wu et al., 2012)
F-HBsAg	Cloning	Forward	CGCGGATCCATGGAGAACATCACAT CAGGA	155
R-HBsAg	Cloning	Reverse	CAGCTCGAGTTAAATGTATACCCAA AGACA	835

133 Genebank accession No. of the reference sequences: HBV real time PCR primer,

134 V01460; HBsAg cloning, AF282918;

135

136 **References**

- 137 Fan, J.Y., Cui, Z.Q., Wei, H.P., Zhang, Z.P., Zhou, Y.F., Wang, Y.P., and Zhang, X.E.  
138 (2008). Split mCherry as a new red bimolecular fluorescence complementation system  
139 for visualizing protein-protein interactions in living cells. *Biochem Biophys Res*  
140 *Commun* 367, 47-53.
- 141 Jalah, R., Rosati, M., Kulkarni, V., Patel, V., Bergamaschi, C., Valentin, A., Zhang,  
142 G.M., Sidhu, M.K., Eldridge, J.H., Weiner, D.B., *et al.* (2007). Efficient systemic  
143 expression of bioactive IL-15 in mice upon delivery of optimized DNA expression  
144 plasmids. *DNA Cell Biol* 26, 827-840.
- 145 Lin, Y., Deng, W., Pang, J., Kemper, T., Hu, J., Yin, J., Zhang, J., and Lu, M. (2016).  
146 The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-  
147 1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy. *Cell Microbiol* 23, 546-545.
- 148 Ni, Y., Sonnabend, J., Seitz, S., and Urban, S. (2010). The pre-s2 domain of the hepatitis  
149 B virus is dispensable for infectivity but serves a spacer function for L-protein-  
150 connected virus assembly. *J Virol* 84, 3879-3888.
- 151 Wu, C.C., Deng, W.Y., Deng, L., Cao, L., Qin, B., Li, S.X., Wang, Y., Pei, R.J., Yang,  
152 D.L., Lu, M.J., *et al.* (2012). Amino Acid Substitutions at Positions 122 and 145 of  
153 Hepatitis B Virus Surface Antigen (HBsAg) Determine the Antigenicity and  
154 Immunogenicity of HBsAg and Influence In Vivo HBsAg Clearance. *J Virol* 86, 4658-  
155 4669.
- 156